07/08 Taiwan BIO Weekly
2025-07-08 |
| Taiwan BIO Weekly |
| TVGH touts platform that diagnoses schizophrenia Press release 4 July, 2025 Taipei Veterans General Hospital (TVGH) on Wednesday touted the world's first artificial intelligence (AI)-powered platform designed to assist in the diagnosis of schizophrenia, saying it has an accuracy of 91.7 percent and is capable of transcending the limits of traditional symptom-based assessments. More... |
| Acer Medical's VeriOsteo OP bone screening system receives medical device approval in Singapore 3 July, 2025 Acer Group's smart healthcare subsidiary, Acer Medical (TW: 6857), announced that its AI-assisted diagnostic software for detecting abnormal bone density, VeriOsteo OP, has officially received marketing approval from Singapore's Health Sciences Authority (HSA). More... (in Chinese) |
| Taiwanese team develops breast cancer treatment 3 July, 2025 A Taiwanese medical team has developed a new treatment for triple-negative breast cancer (TNBC) that tackles treatment-resistance, National Health Research Institutes (NHRI) president Sytwu Huey-kang told a news conference yesterday. More... |
| Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy Press release 2 July May, 2025 Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now exceeding NT$500 million, including seed and early-stage investments, Primo is accelerating its path toward leadership in radioligand theranostics. The company also revealed plans to launch its IPO in 2026, leveraging public market resources to expand R&D capabilities and international reach. More... |
| Lin BioScience's LBS-008 oral drug for late-stage dry AMD completes Phase III enrollment 2 July, 2025 Lin BioScience (TW: 6696), on behalf of its subsidiary Belite Bio, announced that it has completed enrollment of 500 participants in the global Phase III clinical trial (PHOENIX) of its oral drug LBS-008 (Tinlarebant) for the treatment of late-stage dry age-related macular degeneration (Geographic Atrophy, GA). The trial spans the United States, United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia. Tinlarebant is poised to become the first oral drug for treating late-stage dry AMD. More... (in Chinese) |
| HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach Press release 2 July, 2025 [Taiwan's] HanchorBio Inc. (TW: 7827), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA). More... |
| Taiwan's biotech gathers momentum 1 July, 2025 Backed by coordinated efforts from both government and industry, Taiwan's biotechnology sector is expanding steadily, with revenues reaching approximately $23.3 billion in 2023. The industry is positioning itself as an important player in the global biotech value chain. But what will it take for Taiwan to grow into a $32 billion biotech economy? Let's find out. More... |
| Steminent Biotherapeutics submits SCA drug application in Japan, aiming for conditional approval next year 1 July, 2025 Steminent Biotherapeutics (TW: 7729) announced that it has completed the required documentation for the drug registration application in Japan of its stem cell-based new drug Stemchymal, developed for the treatment of spinocerebellar ataxia (SCA), by the end of June. The documents have been officially submitted to its Japanese partner REPROCELL, and aims to obtain conditional approval in Japan as early as next year. More... (in Chinese) |
| Taiwan Highlights Biotech Strengths, Tech Integration, and Global Reach at BIO 2025 30 June, 2025 Taiwan underscored its growing biotech capabilities at the BIO International Convention 2025 through its national pavilion, organized by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), and TAITRA (Taiwan External Trade Development Council). The delegation featured representatives from over 35 Taiwanese companies and several key institutions. Together, they emphasized Taiwan's role in global biotech supply chains, showcasing more than 50 technologies across precision health, CDMO, diagnostics, and digital healthcare. More... |
| Taimed Biologics selected to present at ID Week 2025, showcasing novel anti-HIV ADC 30 June, 2025 Taimed Biologics (TW: 4147) announced that its promising research results on a novel CD4+ cell-targeting antibody-drug conjugate (ADC) for HIV treatment have been selected for presentation at ID Week 2025, a leading global conference in the field of infectious diseases. The poster presentation, titled "Development of Novel CD4+ Cell Targeting Antibody-Drug Conjugates for HIV Treatment," will be exhibited on October 21, 2025, at the Poster Hall of the Georgia World Congress Center in Atlanta, Georgia, USA. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |